Company Overview of G1 Therapeutics, Inc.
G1 Therapeutics, Inc. researches and develops small molecule therapies to address unmet needs in oncology. It offers programs including G1T28-1, to protect bone marrow and other organs from side effects of chemotherapy treatments and radiation. The company was formerly known as G-Zero Therapeutics Inc. G1 Therapeutics, Inc. was founded in 2008 and is based in Research Triangle Park, North Carolina.
79 T.W. Alexander Drive
4401 Research Commons
Research Triangle Park, NC 27709
Founded in 2008
Key Executives for G1 Therapeutics, Inc.
Chief Executive Officer and Director
Co-Founder, Director, and Scientific and Clinical Advisor
Co-Founder and Scientific and Clinical Advisor
Compensation as of Fiscal Year 2015.
G1 Therapeutics, Inc. Key Developments
G1 Therapeutics Announces Initiation of Two Phase 1b/2a Trials of CDK4/6 Inhibitor G1T28 in Small-Cell Lung Cancer
Aug 11 15
G1 Therapeutics, Inc. announced that it has initiated two Phase 1b/2a trials of the CDK4/6 inhibitor G1T28 in patients with small-cell lung cancer (SCLC). G1T28 is an intravenous (IV) therapy being studied as a bone marrow and immune system chemoprotectant in patients with SCLC who are receiving chemotherapy. The two Phase 1b/2a trials consist of an 80-patient randomized first-line study (02 Study) and a 40-patient single-arm second /third-line study (03 Study). 02 Study: G1T28 in Combination with Etoposide and Carboplatin in Extensive-Stage SCLC. This multi-center, randomized, placebo-controlled, study will investigate the potential clinical benefit of G1T28 when administered IV just prior to standard doses of carboplatin and etoposide as a first-line treatment for patients with newly diagnosed extensive-stage SCLC. The study will enroll approximately 80 patients. Outcome measurements include assessment of hematologic parameters and toxicities, infections, chemotherapy dose reductions, utilization of growth factors and blood transfusions, and assessment of anti-tumor activity. 03 Study: G1T28 in Patients with Previously Treated Extensive-Stage SCLC Receiving Topotecan Chemotherapy. This multi-center single-arm study will investigate the potential clinical benefit of G1T28 when administered IV just prior to standard doses of topotecan in patients previously treated for extensive-stage SCLC. The study will enroll approximately 40 patients. Outcome measurements include assessment of hematologic parameters and toxicities, infections, chemotherapy dose reductions, utilization of growth factors and blood transfusions, and assessment of anti-tumor activity. G1T28 demonstrated robust, transient G1 cell-cycle arrest of hematopoietic stem and progenitor cells in a first-in-human Phase 1a trial. The compound was well-tolerated with no dose-limiting toxicities or serious adverse events, displayed an ideal pharmacokinetic /pharmacodynamic profile for use as an IV chemoprotectant, and identified the dose for subsequent trials in SCLC. G1T28 Phase 1a data were presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting.
G1 Therapeutics, Inc. Presents at Wedbush PacGrow Healthcare Conference 2015, Aug-12-2015 10:20 AM
Jul 13 15
G1 Therapeutics, Inc. Presents at Wedbush PacGrow Healthcare Conference 2015, Aug-12-2015 10:20 AM. Venue: Le Parker Meridian, 119 West 56th Street, New York, NY 10019, United States. Speakers: Mark Velleca, Chief Executive Officer and Director.
G1 Therapeutics, Inc. Presents at 35th Annual Canaccord Genuity Growth Conference, Aug-12-2015 09:30 AM
Jul 9 15
G1 Therapeutics, Inc. Presents at 35th Annual Canaccord Genuity Growth Conference, Aug-12-2015 09:30 AM. Venue: InterContinental Boston, 510 Atlantic Avenue, Boston, MA 02210, United States. Speakers: Gregory J. Mossinghoff, Chief Business Officer.
Similar Private Companies By Industry
Recent Private Companies Transactions
February 4, 2015